

SUBJECT INDEX TO VOLUME 1

<ul style="list-style-type: none"> Activating cardiac stem cells 129 <ul style="list-style-type: none"> in adult mammalian heart 129 to repair injured myocardium 129 Acute decompensated heart failure (ADHF) 1 <ul style="list-style-type: none"> inotropic therapy for 3 management of 1 mechanical therapy for 4 neurohormonal aquaretic therapy for 1 novel strategies for 1 ultrafiltration for 4 use of adenosine receptor antagonists 2 use of aortic flow augmentation device 4 use of calcium sensitizers/phosphodiesterase inhibitors 3 use of endothelin receptor antagonists 3 use of natriuretic peptides 2 use of nitric oxide synthases inhibitor 3 use of vasopressin receptor antagonists 1 vasoactive therapy for 2 Advanced atheroma 174 <ul style="list-style-type: none"> shear stress/turbulence in 176 Advanced heart failure 45 <ul style="list-style-type: none"> additional therapies for 48 angina in 47 anxiety in 49 atrial fibrillation in 47 cardiac resynchronization therapy (CRT) in 49 cognitive impairment in 50 depression in 49 dyspnea in 48 fatigue in 48 fluid retention in 48 hospice programs for 50 inotropic therapy for 48 ischemia in 47 mechanical support in 49 mood/morale/adaptation with 49 nausea/constipation in 48 obstructive sleep apnea (OSA) in 48 pain in 48 palliative care approach to 45,50 palpitations in 47 prognosis of 45 psychological issues to 49 rhythm disturbances in 47 sinus node dysfunction in 47 treatment for physical complaints in 47 treatment goals for 46 ventricular arrhythmias in 47 Apoptosis 141 <ul style="list-style-type: none"> adapter molecules in 142 and macrophage 149 effectors in 142 in acute ischemic syndromes 148 in atherosclerotic plaque erosion 146 in atherosclerosis 141 in disease progression 147 in early stages of atherosclerosis 144 in model of cross-talk 142 	<ul style="list-style-type: none"> <ul style="list-style-type: none"> in plaque instability 147 in plaque rupture 148 in thin capped fibroatherom 147 in type I lesions 144 in type II lesions 145 modulation in atherosclerotic lesions 142 regulator proteins in 142 role in atherosclerotic lesion 144 Arterial remodeling 177 Aspirin resistance 203 <ul style="list-style-type: none"> aggregometry of 203 clinical implications of 203 detection of 203 mechanisms of 203 Aspirin 203 <ul style="list-style-type: none"> clinical implications of 208 in alternative pathways of platelet activation 207 in drug interactions 207 in increased platelet turnover 207 inadequate aspirin dosing by 206 incorrect diagnosis of 206 insufficient aspirin bioavailability in 206 mechanisms of 206 patient non-compliance of 206 resistance of 203 Atherosclerosis 142,171 <ul style="list-style-type: none"> apoptotic stimuli in 142 effector pathways in 142 molecular/cellular basis of 171 nitric oxide 172 oxidative stress in 174 signal transduction pathways in 175 Atherosclerotic plaque imaging 185 Atrial fibrillation (AF) 103,228 <ul style="list-style-type: none"> cardioembolic events 228 duration of 103 prolonged signal-averaged P wave duration in 103 recurrence of 103 SAECG recordings of 104 study population design of 103 Biodegradable stents 192 Blood pressure 213 <ul style="list-style-type: none"> effect of age 213 Bone marrow stem cells 129 <ul style="list-style-type: none"> differentiate into cardiomyocytes 130 mobilized for myocardial regeneration 130 to repair injured myocardium 130,132 Calcific aortic stenosis (AS) 231 <ul style="list-style-type: none"> calcification in 232 effect an bicuspid aortic valve 232 experimental/clinical data of 234 genetic factors of 233 histology of 231
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

in inflammation.....	232	anastomosis for	240
in medical treatment alternatives	231	coarctation resection with extended end-to-end	
molecular/cellular mechanisms of.....	231	anastomosis for.....	242
pathophysiology of.....	232	coarctation resection with interposition graft for	242
predisposing/aggravating factors of.....	232	diagnostic issues of	239
role of lipids	232	evolution of therapeutic options for	239
similarities/differences with atherosclerosis	233	historical therapeutic options for	240
Cardiac repair	131	long-term issues of.....	244
experimental evidence of bone marrow stem		subclavian flap aortoplasty for	241
cells for	132	therapeutic issues of.....	239
experimental evidence of myoblasts for	131	transcatheter therapy for.....	243
implantation of autologous for	131	Coronary angiography	74
Cardiomyocytes	128	in perioperative evaluation	74
in adult heart	128	Coronary artery disease	81
into cell cycle to repair injured myocardium	128	apolipoprotein A-I mimetic peptides for	81
Cardiomyocyte function	248	treatment of	81
endothelial modulation of.....	248	Coronary artery imaging.....	184
Cardiovascular magnetic resonance (CMR) imaging.....	181	Coronary microvascular endothelial dysfunction.....	247
in cardiac/paracardiac masses	186	in cardiac disease.....	247
in aorta/great vessels.....	186	in heart failure development	247,250
in arrhythmogenic right ventricular		Drug eluting stents (DES).....	189
cardiomyopathy	185	dedicated to bifurcation lesions.....	192
in congenital heart disease.....	186	designs of drug-delivery platforms for.....	191
in functional stress testing	181	polymer free/polymer biodegradable drug	
in ischemic heart disease.....	181	eluting stents.....	192
in myocardial viability.....	183	technologies for	189
in pericardial disease.....	186	Exercise testing	153
in pulmonary venous anatomy.....	186	arrhythmias in	158
indications for	185	contraindications of	155
Cardiovascular risk.....	215	diagnostic use of	158
correlation of pulse pressure with	215	effect on blood pressure	156
Cardiovascular system	121	effect on heart rate	155
direct effects of EPO on	121	findings of	155
Chemoreception	65	gas exchange analysis in	156
anatomy of	65	gender in	160
basic mechanisms of	65	hemodynamic responses in	155
biological mechanisms of	66	indications for	158
in fetus	66	protocols of	155
Chronic heart failure (CHF)	117	ramp testing in	155
anaemia in	117	recent advances in	153
characteristics of	117	risk assessment in	154
clinical consequences of	121	safety precautions of	154
erythropoietin deficiency in	119,121	scores of	160
haemodilution in	119	ST analysis in	157
iron deficiency in	119	Failing hearts	37
mechanisms of	117	oxidative stress in	37
physiological consequences of	120	Heart failure	7,17,29,37,248
polycythaemia in	117,123	adenine nucleotide translocator in	23
prevalence of	117	adenylate kinase in	22
renal function in	119	and mitochondrial oxidative stress	37
resistance in	119	assessment of	29
risk factors of	120	augmented muscle reflex in RATS with	8
role of pro-inflammatory cytokines	119	cardiac sympathetic innervation in	29
treatment of	121	Coarctation of aorta	239
Coarctation of aorta	239	anatomic issues of.....	239
anatomic issues of.....	239	coarctation patch aortoplasty for.....	241
coarctation patch aortoplasty for.....	241	coarctation resection with end-to-end	
coarctation resection with end-to-end			

clinical implications of	12	Muscle interstitial ATP	10
consequences of oxidative stress in	38	effect of static exercise	10
coordination with KATP	24	Muscle pressor reflex	9
creatine kinase kinetics in	20	role of ASIC in	9
drug intervention/cardiac MIBG activity in	31	role of ATP	10
effect on myocardial energy transport	17	role of P2X receptor in	10
free energy release per ATP hydrolysis in	19	role of VR1 receptor	9
glycolytic phosphotransfer in	23	Myocardial perfusion imaging	182
high energy phosphate metabolism in	17	Myocardial regeneration	127
mechanisms of impairment of sympathetic		clinical trials of	131
activity in	30	<i>ex vivo</i> approach for	131
mechanisms of oxidative stress in	38	<i>in vivo</i> approach for	128
mechanisms responsible for endothelial		Noncardiac surgery	71
dysfunction in	248	ambulatory electrocardiographic monitoring for	74
metabolic signaling in	24	assessing perioperative cardiac risk in	71
model by surgical ligation	8	dobutamine stress echocardiography for	73
muscle mechano/metaboreflex in	11	evaluating of	71
muscle mechanoreceptor mediated reflex in	13	exercise electrocardiogram for	73
muscle metaboreceptor mediated reflex in	13	in arrhythmias	76
muscle reflex modulation in	7	in conduction defect	76
novel pathophysiological insight of	37	in congenital heart disease	76
novel therapeutic strategies of	41	in congestive heart failure	76
pathological conditions of	20	in hypertrophic cardiomyopathy	76
prognostic implications of	29	in left ventricular dysfunction	76
prospective of	13	in patients with specific cardiovascular	
role of P2X receptors	11	conditions	75
role of VR1	11	in valvular heart disease	76
targeting oxidative stress in	41	minimizing cardiac risk in	71
treatment strategies for	29,37	monitoring for perioperative myocardial	
Hypertension	103	infarction in	75
roles of	103	myocardial perfusion imaging for	73
Hypertrophic cardiomyopathy	53	other strategies for reducing perioperative risk in	75
clinical aspects of	53	pharmacological stress test for	73
future directions of	60	post-test probability of cardiac complications	
genetic screening of	58	after	74
genotype-phenotype correlation of	56	risk of perioperative cardiac events during	71
impact of genetics on treatment of	59	Osmolar contrast media	112
invasive therapeutic interventions in	60	Oxidative stress	38
modifier genes in	55	and skeletal muscle dysfunction	41
molecular genetic aspects of	53,55	mitochondrial DNA damage in	38
pathogenesis of	57	myocardial damage in	41
phenotypic expression of	54	P2X receptor	10
prevalence of	54	enhanced mechanoreceptor-evoked muscle	
Inflammation	90	response by	10
blood-borne markers of	90	Pacemaker implantation	228
Large artery stiffness	214	clinical implications of	228
pathophysiology of	214	complications of	228
Lethal arrhythmias	29	Pacemaker syndrome	227
assessment of	29	in quality of life	227
cardiac sympathetic innervation in	29	Peripheral chemoreceptors	65
prognostic implications of	29	biological mechanisms of	66
therapeutic for	29	in sudden infant death syndrome	65
Magnetic resonance imaging	85	integrated physiology of	66
role in myocardial iron assessment	85		
Medical therapy	75		
role of	75		

Peroxisome proliferating activated receptor (PPAR)	89	hemofiltration in	112
signaling of	90	hydration in	111
Peroxisome proliferating activated receptor (PPAR)		morbidity of	109
ligands	89	mortality of	109
anti-atherogenic role of	89	<i>N</i> -acetylcysteine (NAC) in	112
Physiological pacing.....	225	natural history of	109
in heart failure	225	pathophysiology of	110
in patient survival	225	prevention of	110
Plaque rupture	171	risk factors of	109
development of.....	174	Repair injured myocardium	134
inflammation in.....	174	implantation of ES-derived cardiomyocytes for ..	135
molecular/cellular basis of.....	171	implantation of fetal cardiomyocytes for	135
nitric oxide	172	implantation of other autologous petential	
signal transduction pathways in	175	cell types	134
Platelet activation.....	205	<i>in vitro</i> approach for	135
cellular assessment of.....	205	Revascularization	72
Postconditioning.....	195	Stents eluting antiproliferative agents.....	191
as paradigm for myocardial protection.....	195	Stents eluting anti-thrombotic agents.....	191
clinical implications for.....	199	Stents eluting immunosuppressive agents.....	189
eng-effectors of	199	Stents eluting prohealing agents.....	190
historical perspective of.....	196	Sudden cardiac death	33
in graded reperfusion.....	196	impaired cardiac MIBG activity in	33
initial characterization of.....	195	Sudden infant death syndrome (SIDS)	67
mechanisms of.....	198	clinical/epidemiological features of	67
mediators of.....	1998	Sympathetic nervous system (SNS)	7
mitochondrial permeability transition pore of	199	Thrombosis.....	174
proposed triggers of.....	198	shear stress/turbulence in	176
role of adenosine	198	Tuberculous pericarditis	165
role of nitric oxide.....	198	clinical illustrative case of	165
role of PI3-kinase/ERK1/2.....	1998	clinical manifestations of	167
role of reactive oxygen species	198	diagnosis of	168
PPAR- α ligands	90	management of	168
and blood-borne indicators of inflammation	92	pathogenesis of	167
clinical outcomes of therapy by	93	pathology of	167
metabolic actions of	90	Vascular endothelial dysfunction.....	171
vascular actions of	92	pathophysiology of.....	171
PPAR- γ ligands	93	Vascular injury	171
and blood-borne indicators of inflammation	95	consequences of	171
clinical outcomes of therapy by	95	Vulnerable plaque.....	177
metabolic actions of	93	identification/treatment of.....	177
vascular actions of	94	Wide pulse pressure.....	213
Preoperative coronary angioplasty	74	in elderly.....	213
role of	74		
Preoperative coronary artery bypass surgery	74		
role of	74		
Radiocontrast nephropathy (RCN)	109		
dopamine receptor agonism in	113		